Lasmiditan: an additional therapeutic option for the acute treatment of migraine

References

• Vincent W. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
   Web of Science ®Google Scholar
• Diamond M, Freitag F, Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349.
   PubMed Web of Science ®Google Scholar
• Blau JN. Migraine: theories of pathogenesis. Lancet. 1992;339:1202–1207.
   PubMed Web of Science ®Google Scholar
• Bose P, Karsan N, Goadsby PJ. The migraine postdrome. Continuum (Minneap Minn). 2018;24:1023–1031.
   PubMedGoogle Scholar
• Soheili-Nezhad S, Sedghi A, Schweser F, et al. Structural and functional reorganization of the brain in migraine without aura. Front Neurol. 2019;10. DOI:10.3389/fneur.2019.00442.
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–1602.
   PubMed Web of Science ®Google Scholar
• Allena M, Steiner TJ, Sances G, et al. Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the eurolight project. J Headache Pain. 2015;16:1–9.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.
   PubMed Web of Science ®Google Scholar
• Charles A. Vasodilation out of the picture as a cause of migraine headache. Lancet Neurol. 2013;12:419–420.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Phase-by-phase A. Review of migraine pathophysiology. Headache. 2018;58:4–16.
   Web of Science ®Google Scholar
• Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–323.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache J Head Face Pain. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2017;14:1–17.
   PubMedGoogle Scholar
• Goadsby PJ. Primary headache disorders: five new things. Neurol Clin Pract. 2019;9:233–240.
   PubMedGoogle Scholar
• Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16:968–981.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache J Head Face Pain. 2008;48:1157–1168.
   PubMed Web of Science ®Google Scholar
• Mayans L (University of Kansas School of Medicine, Wichita K, Walling A (University of Kansas School of Medicine, Wichita K. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97:243–251.
   PubMed Web of Science ®Google Scholar
• Ashina M. Migraine. Ropper AH editor. N Engl J Med. 2020; 383:1866–1876.
   PubMed Web of Science ®Google Scholar
• Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35:118–131.
   PubMed Web of Science ®Google Scholar
• Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62:563–568.
   PubMed Web of Science ®Google Scholar
• Diener HC. The risks or lack thereof of migraine treatments in vascular disease. Headache. 2020;60:649–653.
   PubMed Web of Science ®Google Scholar
• Cameron C, Kelly S, Hsieh S-C, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache J Head Face Pain. 2015;55:221–235.
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D, Chan C, Villar-Martínez MD, et al. Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review. Headache. 2019;59:3–19.
   PubMed Web of Science ®Google Scholar
• Moisset X, Pereira B, Ciampi De Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2020;21:142.
   PubMed Web of Science ®Google Scholar
• Reuter U, McClure C, Liebler E, et al. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J Neurol Neurosurg Psychiatry. 2019;90:796–804.
   PubMed Web of Science ®Google Scholar
• Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—Lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12:1–22.
   Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–350.
   PubMed Web of Science ®Google Scholar
• Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33:1053–1071.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al., Lasmiditan is an effective acute treatment for migraine. Neurology. 91(24);2018:e2222-e2232.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894–1904.
   PubMed Web of Science ®Google Scholar
• Xavier AS, Lakshmanan M, Gunaseelan V. The journey of the non-vascular relief for migraine: from “triptans” to “ditans”. Curr Clin Pharmacol. 2017;12:36–40. .
   PubMed Web of Science ®Google Scholar
• Deen M, Hougaard A, Hansen HD, et al. Association between sumatriptan treatment during a migraine attack and central 5-HT 1B receptor binding. JAMA Neurol. 2019;76:834.
   PubMed Web of Science ®Google Scholar
• Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action-review of a selective 5-HT 1F agonist. J Headache Pain. 2020;3:1–13.
   Google Scholar
• Lamb YN. Lasmiditan: first Approval. Drugs. 2019;79:1989–1996.
   PubMedGoogle Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019;176:4681–4695.
   PubMed Web of Science ®Google Scholar
• Cohen ML, Schenck K. 5-hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999;290:935–939.
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30:1159–1169.
   PubMed Web of Science ®Google Scholar
• Capi M, De Andrés F, Lionetto L, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26:227–234.
   PubMed Web of Science ®Google Scholar
• Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8:46–54.
   PubMed Web of Science ®Google Scholar
• clinicaltrial.gov. NCY02233296 [Internet]. 2018. Available from: https://clinicaltrials.gov/ct2/show/nct02233296
   Google Scholar
• Curto M, Cipolla F, Cisale GY, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2020;21:147–153.
   PubMed Web of Science ®Google Scholar
• clinicaltrial.gov. NCT03937648 [Internet]. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03937648
   Google Scholar
• clinicaltrial.gov. NCT03465436 [Internet]. 2020. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03465436
   Google Scholar
• Tsai M, Case M, Ardayfio P, et al. Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin Pharmacol Drug Dev. 2020;9:629–638.
   PubMed Web of Science ®Google Scholar
• clinicaltrial.gov. NCT03076970 [Internet]. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03076970
   Google Scholar
• clinicaltrial.gov. NCT03308669 [Internet]. 2019. [cited 2019 Nov 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03308669
   Google Scholar
• clinicaltrial.gov. NCT03009162. 2019.[cited 2019 Nov 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03009162
   Google Scholar
• clinicaltrial.gov. NCT03040479 [Internet]. 2019. [cited 2019 Nov 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03040479
   Google Scholar
• Tfelt-Hansen PC, Olesen J. The 5-HT 1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012;13:271–275.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia. 2010;30:1170–1178.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11:405–413.
   PubMed Web of Science ®Google Scholar
• Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294–304. .
   Web of Science ®Google Scholar
• Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 2019;39:1343–1357.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Lombard L, Ruff DD, et al. Trajectory of migraine-related disability following long-Term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21. DOI:10.1186/s10194-020-01088-4.
   Web of Science ®Google Scholar
• Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2‐hour post‐dose efficacy of lasmiditan for the acute treatment of difficult‐to‐treat migraine attacks. Headache J Head Face Pain. 2020;60:1601–1615.
   PubMed Web of Science ®Google Scholar
• Hou M, Xing H, Li C, et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1Freceptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2020;21:1–12.
   PubMed Web of Science ®Google Scholar
• Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20:84.
   PubMed Web of Science ®Google Scholar
• Brandes JL, Klise S, Krege JH, et al. Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study. Cephalalgia Rep. 2020;3:251581632095817.
   Google Scholar
• Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019;39:957–966.
   PubMed Web of Science ®Google Scholar
• Smith T, Krege JH, Rathmann SS, et al. Improvement in function after lasmiditan treatment: post hoc analysis of data from phase 3 studies. Neurol Ther. 2020;9:459–471.
   PubMed Web of Science ®Google Scholar
• Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20. DOI:10.1186/s10194-019-1044-6.
   PubMed Web of Science ®Google Scholar
• Dunkley EJC, Isbister GK, Sibbritt D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM - Mon J Assoc Physicians. 2003;96:635–642.
   PubMed Web of Science ®Google Scholar
• Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40:19–27.
   PubMed Web of Science ®Google Scholar
• clinicaltrial.gov. NCT04396236 [Internet]. 2021. [cited 2019 Mar 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04396236?cond=NCT04396236&draw=2&rank=1
   Google Scholar
• clinicaltrial.gov. NCT04396574. 2021.
   Google Scholar
• Pearlman EM, Wilbraham D, Dennehy EB, et al. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020;35:1–11.
   Web of Science ®Google Scholar
• Wilbraham D, Berg PH, Tsai M, et al. Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study. J Clin Pharmacol. 2020;60:495–504.
   PubMed Web of Science ®Google Scholar
• Rau JC, Navratilova E, Oyarzo J, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia. 2020; 40.
   Google Scholar
• Van Hoogstraten WS, Maassenvandenbrink A. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain. 2019;20:1–7.
   PubMed Web of Science ®Google Scholar